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Abstract 
A novel strain of corona virus, namely, COVID-19 has been identified in Wuhan city of 
China in December 2019. There are no specific therapies available and investigations regarding 
the treatment of the COVID-19 are still lacking. This prompted us to perform in silico studies on 
the COVID-19 protease with anti-malarial compounds in the search of potential inhibitor. We 
have calculated log P and log S values in addition to molecular docking and PASS predictions. 
Among the seven studied compounds, mepacrine appears as the potential inhibitor of the 
COVID-19 followed by chloroquine, hydroxychloroquine and phomarin.  Therefore, these anti-
malarial drugs and specially mepacrine may be potential drug candidate for the treatment of this 
novel corona virus. Further detailed clinical studies are invited to investigate their potential 
medicinal use for the COVID-19.  
Keywords: COVID-19; Inhibitors; Anti-malarial drugs; Mepacrine; Chloroquine; Molecular 
Docking. 
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Introduction 
At the beginning of this year, the corona virus infection disease (COVID-19) was 
recognized in Wuhan, China [1]. Subsequently, the COVID-19 started spreading across the 
globe, putting the whole world on high alert [2–5]. This led to 655 total cases and 18 deaths all 
over the world including China and 9 other countries till 23 January 2020 [6].  In India, the first 
case of the COVID-19 was reported in Kerala on 30 January 2020. As of 20 March 2020, there 
are 230 cases and 4 deaths as reported by the Ministry of Health and Family Welfare, 
Government of India [7]. According to a report of the world health organization (WHO) dated 17 
March 2020, there are a total of 0.18 million cases of the COVID-19 worldwide, causing almost 
7.5 thousand deaths and counting [8].  
Corona viruses infect humans and vertebrate animals, affecting their respiratory, 
digestive, liver and central nervous systems [9]. Since the inception of the COVID-19 at the end 
of 2019, the continuous efforts have been made in the research and development of the 
diagnostics, therapeutics and vaccines for this novel corona virus [10]. Based on the results of 
some clinical trials, it has been reported [11] that chloroquine phosphate, an anti-malarial drug, 
has a certain curative effect on the COVID-19. In particular, chloroquine phosphate is 
recommended to treat COVID-19 associated pneumonia in larger populations in the future. This 
motivated us to perform a systematic study on some anti-malarial drugs using molecular docking 
and reinvestigate their biological activities and pharmacological effects. Such studies become 
important as they offer some insights into structure-based drug design. Recently, Lin et al. [12] 
have reported the structure-based stabilization of non-native protein-protein interactions of the 
corona virus in antiviral drug design. However, there exists no systematic study on the inhibition 
of the corona virus by anti-malarial drugs to the best of our knowledge. Therefore, we believe 
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that this study should offer better insights into the binding and interaction of anti-malarial drugs 
with the COVID-19 receptor. 
Methodology 
To identify the potential binding sites for anti-malarial compounds, we have been 
performed an automated in silico molecular-docking procedure using the SwissDock web server 
[13, 14], which is based on the docking algorithm EADock ESS. We have used the main 
protease in corona viruses as a potential target protein for COVID-19 obtained from the RCSB 
protein data bank (PDB ID: 6LU7) [15]. The processed coordinates file for each of the ligands 
and COVID-19 protein (6LU7) has been uploaded, and docking was performed using the 
‘Accurate’ parameter option, which is most exhaustive in terms of the binding modes sampled.  
We have also calculated lipophilicity (log P) and aqueous solubility (log S) ALOGPS 2.1 
program [16]. This program is based on electrotopological state indices and associative neural 
network modeling developed by Tetko et al. [17]. The log P and log S are two very important 
parameters for quantitative structure-property relationship (QSPR) studies. In order to explore 
and predict the pharmacological effects and biological activities of molecules, we have used 
PASS software [18]. The PASS predicts 900 pharmacological effects, molecular mechanisms of 
action, mutagenicity, carcinogenicity, teratogenicity and embryotoxicity.            
Results and Discussion     
We have chosen seven popular anti-malarial compounds as a ligand to the COVID-19 
protease namely mepacrine (1), chloroquine (2), quinine (3), hydroxychloroquine (4), artemisinin 
(5), phomarin (6) and proguanil (7). The molecular structures of these drugs are displayed in Fig. 
1. In order to assess and compare their biological activity, we have computed their log P and log 
S values as listed in Table 1. Log P is closely associated with the transport property of drugs and 
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their interaction with receptors whereas log S is an important factor affecting its bioavailability.  
One can see that the log P values of compounds 1-7 lie in the range 6.13-1.90. Chloroquine (2) 
has a log P value of 5.28 followed by hydroxychloroquine (4) with a log P of 3.87. More 
interestingly, mepacrine (1) has the highest log P of 6.13 among all seven compounds studied in 
this work. The higher log P value suggests that the drug molecules may easily diffuse across the 
cell membranes, as their organic (lipid) solubility is quite large. Likewise, the log S value of 
these anti-malarial compounds ranges between -2.35 and -5.22. In general, about 85% of drugs 
have log S values in the range of -1 to -5, a few have values below -5 but virtually none have 
values below -6 [19]. All log S lies between -1 and -5, except mepacrine (1) having log S slightly 
below -5.  The log S values further confirm the permeability of these molecules across cell 
membranes. In particular, the compounds (1), chloroquine (2), hydroxychloroquine (4) and 
phomarin (6) seem to be more biologically active and potent with log P > 3. 
 
 
Fig. 1. Molecular structures of anti-malarial compounds as possible inhibitors for 6LU7 
(COVID-19 protease). 
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This study has been focused on the main protease in the novel corona virus as a potential 
target protein for COVID-19 treatment. The 6LU7 is the main protease found in the COVID-19, 
which has been deposited as a PDB file in early February 2020. Therefore, we have chosen 
6LU7 as a potential target for molecular docking studies. The molecular docking calculations 
have been performed as blind, i.e., covered the entire protein surface, not any specific region of 
the protein as the binding pocket in order to avoid sampling bias. The output clusters have been 
obtained after each docking step and ranked according to the full fitness (FF) score by the 
SwissDock algorithm. A greater negative FF score suggests a more favorable binding mode 
between ligand and receptor with a better fit. 
 
Table 1: Calculated parameters of anti malarial compounds as possible COVID-19 inhibitors.  
S.No. Anti malarial 
compounds 
Log P Log S Residue 
& 
Bond 
lengths 
Binding 
affinity 
(kcal/mol) 
FF 
score 
1 Mepacrine 
(C23H30ClN3O) 
6.13 -5.22 GLU166 
(2.663 Å) 
-8.89 -1189.0 
2 Chloroquine 
(C18H26ClN3) 
5.28 -4.26 GLY143 
(2.321 Å) 
-8.15 -1208.0 
3 Quinine 
(C20H24N2O2) 
2.82 -2.99 HSD163 
(2.377 Å) 
-7.77 -1144.0 
4 Hydroxychloroquine 
(C18H26ClN3O) 
3.87 -4.11 PHE140 
(2.501 Å) 
-7.62 -1184.0 
5 Artemisinin 
(C15H22O5) 
2.52 -2.35 GLY143 
(2.447 Å, 
2.369 Å) 
-7.34 -1187.0 
6 Phomarin 
(C15H10O4) 
3.04 -3.35 GLY143 
(2.462 Å) 
GLU166 
(2.607 Å) 
-7.13 -1192.0 
7 Proguanil 
(C11H16ClN5) 
1.90 -2.95 LEU141 
(2.262 Å) 
-6.69 -1347.0 
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The results of molecular docking are displayed in Fig. 2.  The docking parameters such as 
binding energy, FF score along with the amino acids (residues) found in the active site pockets of 
6LU7 have been also listed in Table 1. The binding energies (affinities) obtained from docking 
of 6LU7 with ligands mepacrine (1), chloroquine (2), quinine (3), hydroxychloroquine (4), 
artemisinin (5), phomarin (6) and proguanil (7) are -8.86, -8.15, -7.77, -7.62, -7.34, -7.13 and -
6.69 kcal/mol respectively. The affinity of drug compounds depends on the type of bonding that 
occurs with the active site of the protein. The results of docking analyses show the mepacrine (1) 
forms H-bond (bond length = 2.663 Å) with the glutamate (GLU-166), a polar amino acid. On 
the contrary, chloroquine (2) forms H-bond (bond length = 2.321 Å) with the glycine (GLY-
143), a non-polar amino acid. Unlike 2, quinine (3) and hydroxychloroquine (4) form H-bonds 
with the histidine (HSD-163), a polar amino acid (bond length = 2.377 Å) and phenylalanine 
(PHE-140), an aromatic amino acid (bond length = 2.501 Å). Artemisnin ((5) forms two H-bonds 
of bond lengths 2.447 Å and 2.369 Å with the same amino acid (GLY-143). Phomarin (6) also 
forms two H-bonds, one with the GLY-143 (bond length = 2.462 Å) and another with the GLU-
166 (bond length = 2.607 Å). Proguanil (7) forms H-bond of 2.262 Å with the leucine (LEU-
141), a non-polar amino acid. The binding modes of different anti-malarial compounds with the 
6LU7 receptor have been shown in Fig. 2 as well. Thus, our docking analyses suggest that the 
COVID-19 protease (6LU7) can be inhibited by anti-malarial drug compounds. Based on the 
binding affinity, the inhibition potential of these compounds can be ranked as; 1 > 2 > 3 > 4 > 5 
> 6 > 7. Combining the results of log P and log S with the docking, we can expect that the 
compounds 1, 2, 4 and 6 should behave as potential inhibitors of the COVID-19.  
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Fig. 2. Active binding sites of 6LU7 (COVID-19 protease) explored by molecular docking. 
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For the purpose of drug design, it is desirable to analyze the detailed biological activities 
or possible pharmacological effects along with toxicity or possible adverse effects of the drug 
compounds. Therefore, we have predicted activity spectra of anti malarial compounds using the 
PASS software. This prediction is based on the study of structure activity relationships (SAR) for 
the training set including about 50,000 drugs, drug‐candidates and lead compounds whose 
biological activity has been reported experimentally. An average accuracy of prediction in 
leave‐one‐out cross‐validation is about 85% [18]. In supplementary Table S1, we have listed the 
pharmacological effects as well as adverse affects of these compounds with Pa > 70%. This is to 
ensure that the molecules will most likely exhibit these activities in the experiment. Furthermore, 
the probability that the molecules have several closely analogous drugs is quite high. These 
results of PASS prediction might be useful during clinical trials and drug development stage of 
the COVID-19.   
Concluding Remarks 
We have performed a systematic study on anti-malarial compounds in the search of 
potential inhibitors for novel corona virus, COVID-19 protease. Based on the binding affinity as 
well as log P and log S values, mepacrine appears as the most powerful inhibitor among seven 
compounds studied here. Other potential inhibitors of COVID-19 protease include chloroquine, 
hydroxychloroquine and phomarin. Note that chloroquine has already been recommended to treat 
COVID-19 associated pneumonia [11]. While this manuscript was prepared, another research 
based on clinical trials suggested [20] that hydroxychloroquine added with azithromycin is very 
effective in the treatment of the COVID-19. Therefore, we suggest prompt clinic trials of these 
compounds or their suitable combinations, in general with mepacrine with special attention. Our 
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PASS predictions may be useful for clinical trials of these inhibitors of COVID-19. Further 
studies in these directions are in progress in our lab and shall be reported shortly.  
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